Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab

Table 1

Studies of mastocytosis treated with omalizumab.

Study	Patients ()	Dose	Effect
Systemic mastocytosis
Carter et al., 2007 [7]	2	300 mg/4 weeks	Patient I: no further anaphylactic episodes
			Patient II: reduced gastrointestinal and anaphylactic episodes
Pitt et al., 2010 [8]	1	300 mg/4 weeks	No further anaphylactic episodes
Kontou-Fili et al., 2010 [9]	1	300 mg/4 weeks	No further anaphylactic episodes
Douglass et al., 2010 [10]	1	150 mg/4 weeks	No further anaphylactic episodes or cardiac arrest
Paraskevopoulos et al., 2013 [11]	1	300 mg/4 weeks	No further anaphylactic episodes
Kibsgaard et al., 2014 [12]	1	300 mg/4 weeks	No further anaphylactic episodes
Cutaneous mastocytosis
Siebenhaar et al., 2007 [13]	1	150 mg/4 weeks	Reduced cutaneous symptoms
Matito et al., 2013 [14]	1	450 mg/4 weeks	Reduced cutaneous symptoms
Sokol et al., 2014 [15]	1	375 mg/2 weeks	Reduced cutaneous symptoms